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The influence of infarct location on arterial patency, left 
ventricular function and mortality after 150 mg of intrave- 
nous recombinant tissue-type plasminogen activator (rt- 
PA) and selective coronary angioplasty was studied in 386 
patients with acute myocardial infarction. In 329 patients 
with acute and 1 week angiograms, the 90 min infarct- 
related artery patency rate after rt-PA in the left anterior 
descending, the left circumflex and the right coronary 
artery was 77, 68 and 68%, respectively. Angioplasty, 
performed in half the patients, resulted in a final acute 
patency rate of 93%, which was not related to arterial 
distribution. Repeat catheterization and revascularization 
were required in 12% of patients before day 7 and were 
independent of arterial distribution. The reocclusion rate 
for the right coronary artery (21%) was higher than that 
for the left anterior descending (12%) or left circumflex 
(5%) artery (p = 0.01). 
Acute and 1 week contrast ventriculograms suitable for 
analysis were available in 266 patients. Whereas serial left 
Although thrombolytic therapy is generally assumed to be 
more beneficial in anterior than in inferior myocardial infarc- 
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ventricular ejection fraction did not improve during the 
course of this study, serial regional wall motion (centerline 
chord method) improved in each arterial distribution. The 
in-hospital mortality rate of 6% was not related to arterial 
distribution, although death was twice as likely with prox- 
imal compared with distal lesions. Ten of 11 patients who 
died in the group with the left anterior descending artery as 
the infarct-related artery had a lesion proximal to the first 
septal perforator branch. 
Thus, whereas 90 min reperfusion rates were higher in 
the left anterior descending artery and 7 day reocclusion 
rates were higher in the right coronary artery, infarct 
location did not influence improvement in left ventricular 
function. Until further mortality data from large prospec- 
tive randomized trials are available, there does not appear 
to be justification based on improved patency and regional 
wall motion to exclude patients with inferior infarction 
from reperfusion therapy. 
(J Am Co11 CardiolI989;13:12-8) 
tion, results from the randomized trials with intravenous 
streptokinase do not clearly support that contention. Both 
the Netherlands Interuniversity Cardiology Institute trial (l- 
4) and the German Intravenous Streptokinase in Myocardial 
Infarction (ISAM) trial (5,6) reported statistically significant 
improvement in infarct size, regional wall motion and left 
ventricular ejection fraction independent of infarct location 
even though reocclusion rates were higher in inferior infarc- 
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tion. Nevertheless, improved survival was not consistently 
demonstrated by the randomized trials. Although mortality 
was significantly reduced by streptokinase after anterior 
infarction in the Netherlands (I) and the Italian Gruppo 
Italian0 per lo Studio della Streptochinasi nell’Infarto Mio- 
cardico (GISSI) trials (7), it was not reduced in the ISAM 
trial (5,8). A statistically insignificant trend toward mortality 
reduction after streptokinase therapy in inferior infarction 
was reported by all three trials (4,7.8), perhaps because of 
the low mortality rates in the placebo-treated patients after 
inferior infarction, increasing the sample sizes required to 
detect a survival benefit. 
Recombinant tissue-type plasminogen activator (rt-PA) 
has been shown to be superior to streptokinase in reperfus- 
ing acutely occluded coronary arteries (9.10). The efiect of 
infarct location on treatment results, however, has not 
clearly been defined. Among others, two multicenter trials 
without placebo control, the Thrombolysis in Myocardial 
Infarction (TIMI) trials (IO) and the Thrombolysis and 
Angioplasty in Myocardial Infarction (TAMI) trials (I I), 
have been evaluating the results of intravenous rt-PA and 
coronary angioplasty in treating acute myocardial infarction. 
In this study, the results of the TAMI-I trial were analyzed 
to determine the influence of infarct location on arterial 
patency. left ventricular function and mortality after rt-PA 
therapy and selective angioplasty in acute myocardial infarc- 
tion. 
Methods 
Study patients. From December 10, 1985 to October 31. 
1986, 386 patients with acute myocardial infarction by clin- 
ical, electrocardiographic (ECG) and enzymatic criteria 
were prospectively enrolled in the TAMI-I trial (11). Inclu- 
sion criteria were: I) chest pain with a duration of <4 h or <6 
h if severe and persistent: 2) 2 1 mm ST segment elevation in 
two contiguous ECG leads; and 3) age ~76 years. Exclusion 
criteria were: I) chest pain relieved by nitroglycerin or ~20 
min in duration: 2) recent history of trauma. surgery, stroke 
or bleeding; 3) previous coronary artery bypass graft sur- 
gery; 4) previous Q wave infarction in the distribution of the 
infarct-related artery: and 5) cardiogenic shock. Approval by 
the institutional review board was granted at each site before 
enrollment. Informed consent was obtained from each pa- 
tient. 
Study design. Patients received 150 mg of intravenous 
rt-PA over 6 to 8 h (predominantly a single chain preparation 
[Genentech]). In the first 178 patients, the dose was 60 mg 
during the 1st h, 20 mgih during the 2nd and 3rd h and 10 mg 
for each of the last 5 h. In the final 208 patients, the dose 
during the 1st h was 1 .O mgikg of body weight with a 
maximum of 90 mg; the remaining dose was given in equal 
amounts per hour in a 5 h maintenance infusion. For both 
regimens, IO% of the dose for the 1st h was administered 
intravenously as a bolus. 
Cardirtc ctrtheterizrrtion was performed emergently 
through either the femoral or the brachial artery. Intrave- 
nous heparin (5,000 U) was administered after access was 
achieved. Ninety minutes after the initiation of the rt-PA 
infusion, the infarct-related artery was visualized in multiple 
projections with up to four contrast injections. Patency was 
determined after the final injection according to the classifi- 
cation of the TIM1 trial (10). Coronary arteriography was not 
performed in two patients. In 96 patients (25%), the 90 min 
angiogram demonstrated occlusion; 85 of these patients 
underwent coronary angioplasty in an attempt to restore 
arterial patency. Of the 288 patients (7570 with a patent 
infarct-related artery. 91 were believed not to have anatomy 
amenable to angioplasty. The remaining 197 patients were 
randomly assigned to receive either immediate (99 patients) 
or elective (98 patients) coronary angioplasty 7 to IO days 
later. An additional 5.000 U of heparin was given to patients 
receiving angioplasty, which was performed only in the 
infarct-related artery. Contrast left ventriculography was 
performed before angioplasty was attempted if the patient 
&as hemodynamically stable. 
All prrtirnt.\ KYWJ admitted to the corontir~ care unit. 
where they were treated with 500 to 1,000 U of intravenous 
heparin per hour adjusted to keep the partial thromboplastin 
time at 1.5 to 2 times the control level for 224 h: intravenous 
lidocaine for 24 h: aspirin, 325 mgiday; dipyridamole, 75 mg 
three times per day and diltiazem. 30 to 60 mg four times per 
day. 
Thr cliniud end point of recmwnt ischetnicr IZ‘NS defined 
as >20 min of angina that was not responsive to nitrates and 
was accompanied by ECG ST segment elevation. These 
patients emergently underwent repeat cardiac catheteriza- 
tion. with angioplasty or surgery performed at the discretion 
of the attending cardiologist. Patients receiving medical 
therapy or angioplasty underwent follow-up catheterization 
7 to 10 days after receiving rt-PA to assess arterial patency 
and ventricular function. 
Data analysis. For purposes of this study. 376 of the 386 
patients were grouped by infarct-related artery. Ten patients 
were excluded: five had an undefinable infarct-related ar- 
tery, four did not undergo acute catheterization and one had 
the left main coronary artery as the infarct-related artery. 
Demographic data were obtained by interview. Any compli- 
cations, including death, occurring from symptom onset to 
hospital discharge were noted. Acute patency and reocclu- 
sion data were obtained from the 329 patients who had both 
acute and follow-up coronary arteriograms. Seven day pat- 
ency data were obtained in 291 patients who completed the 
scheduled protocol: 38 patients required an earlier interven- 
tion because of recurrent ischemia. Paired coronary arterio- 
grams were not available in 20 patients who died. in 12 who 
refused the second catheterization. in 2 who had only 
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ventriculography and in 13 others for miscellaneous reasons. 
Arterial patency at 90 min, at the conclusion of the acute 
catheterization and at the follow-up catheterization was 
defined as TIM1 grade 2 or 3 flow. Reocclusion was defined 
as recurrent total occlusion of the infarct-related artery at 
any time after the patient left the cardiac catheterization 
laboratory. Lesion location was defined as proximal or distal 
in relation to the first septal perforator branch of the left 
anterior descending artery, the first obtuse marginal branch 
of the left circumflex artery or the first right ventricular 
branch of the right coronary artery, respectively. 
Left ventricular analysis was performed at the University 
of Michigan Angiographic Core Laboratory by a single, 
blinded observer. End-systolic and end-diastolic right ante- 
rior oblique outlines were traced, digitized and stored on a 
digital radiographic computer (DPS 41OOC, ADAC Labora- 
tories) for subsequent processing. Acute and follow-up ven- 
triculographic studies that were adequately opacified and 
free of ventricular ectopic activity were obtained from 264 
patients. The global ejection fraction was determined by the 
area-length method (12). Regional wall motion for the infarct 
zone was determined by the centerline chord method (13) 
and expressed as standard deviations per chord. 
Statistical analysis. Statistical analysis was performed at 
the Duke University Biostatistical Core Laboratory. Base- 
line demographic variables and patient response character- 
istics were described in terms of percentages for discretely 
valued variables and mean + SD for continuous variables. 
For comparing infarct location groups with respect to dis- 
crete baseline or response variables, standard chi-square 
contingency table analysis was used. For continuous varia- 
bles, comparisons of the left anterior descending, left cir- 
cumflex and right coronary artery infarct location groups 
were performed with use of Kruskal-Wallis nonparametric 
analysis of variance. The significance of improvements in 
global and regional left ventricular function within each 
arterial distribution was assessed using the Wilcoxon signed- 
rank test. Multiple regression analysis was used to assess the 
effects of arterial distribution and lesion location on im- 
provement in global and regional left ventricular function 
after adjusting for the acute levels of global and regional 
function, respectively. All analyses were performed using 
the SAS system of statistical analysis software. 
Results 
Demographic data (Table 1). The infarct-related artery 
was the left anterior descending, the left circumflex and the 
right coronary artery in 153, 48 and 175 patients, respec- 
tively. There were no significant differences among arterial 
distributions in patient age, gender, history of angina, coro- 
nary risk factors or time to treatment. 
Complications (Table 2). Atrioventricular block, supra- 
ventricular tachyarrhythmia and sustained sinus bradycardia 
Table 1. Demographic Data in 376 Patients With Acute 
Myocardial Infarction 
Infarct-Related Artery 
LAD LCX 
No. of patients 153 48 
Age (yr) (mean ? SD) 56211 56+11 
Male gender 122 (78%) 37 (77%) 
History of angina 82 (54%) 28 (58%) 
History of smoking 91 (60%) 31 (65%) 
Hypertension 68 (44%) 19 (40%) 
Diabetes 19 (12%) 10 (21%) 
Hyperlipidemia 17 (11%‘) 6 (13%) 
Family history 54 (35%) 23 (48%) 
Time to Rx (min) (mean 2 SD) 177 ? 66 179 + 59 
RCA Total 
~___ 
175 376 
56 * 10 56 ? 10 
139 (79%) 298 (79%) 
77 (46%) 187 (50%) 
126 (72%) 248 (66%) 
72 (41%) 159 (42%) 
25 (14%) 54 (14%) 
12 (7%) 35 (9%) 
66 (38%) 143 (38%) 
177 t 67 177 2 65 
LAD = left anterior descending coronary artery; LCx = left circumflex 
cononary artery; RCA = right coronary artery; Rx = treatment. 
were more frequent when the infarct-related artery was the 
left circumflex or right coronary artery than when it was the 
left anterior descending artery. Pulmonary edema was more 
frequent when the latter was the infarct-related artery. The 
incidence of ventricular tachyarrhythmia, sustained hypo- 
tension and major bleeding was not influenced by arterial 
distribution. 
Arterial patency (Tables 3 and 4). A statistically insignif- 
icant trend toward a higher reperfusion rate 90 min after 
initiating rt-PA therapy was present when the left anterior 
descending artery was the infarct-related artery. Emergent 
angioplasty was performed in half of the patients, resulting in 
a final patency rate of 93% that was not influenced by arterial 
distribution. Emergent bypass surgery was more common in 
patients with the left anterior descending artery as the 
infarct-related artery. The acute study results reported in 329 
patients were not influenced by excluding the 47 patients 
who did not have repeat coronary arteriography. Urgent 
Table 2. Complications in 376 Patients With Acute 
Myocardial Infarction 
Infarct-Related Artery 
LAD LCX RCA Total 
No. of patients 153 48 175 376 
AV block 8 (5%) 7 (15%) 38 (22%) 53 (14%) 
AfibiAfliSVT I5 (10%) 6 (13%) 31 (18%) 52 (14%) 
VT > 100 78 (51%) 22 (46%) 82 (47%) 182 (48%) 
beats/min/VF 
Sustained sinus 18 (12%) 12 (25%) 49 (28%) 79 (21%) 
bradycardia 
Sustained hypotension 29 (19%) 10 (21%) 36 (21%) 75 (20%) 
Major bleeding 23 (15%) 6 (13%) 24 (14%) 53 (14%) 
Pulmonary edema 31 (20%) 5 (10%) 16 (9%) 52 (14%) 
Afib = atrial fibrillation; Afl = atria1 flutter; AV = atrioventricular; SVT 
= supraventricular tachycardia; VF = ventricular fibrillation; VT = ventric- 
ular tachycardia; other abbreviations as in Table I. 
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Table 3. Arterial Patency After Thrombolytic Therapy in proximal to the acute marginal branch; in five of the nine 
329 Patients patients the lesion was proximal to the first right ventricular 
Infarct-Related Artery branch. 
L.AD LCX RCA Total p Values 
Acute study 
90 min patency 
PTCA 
Final patency 
CABG 
l!rgent restudy 
PTC.4 or CABG 
Day 7 study 
Patency 
Reocclukn 
I, = 133 n =41 
102 (77%) 28 l68R) 
66 (508) 19 (46%) 
I17 (96%) 35 (85%‘) 
I I (W) 1 (it/i) 
17 II?%) 3 (7%) 
a = II6 n = 3X 
IfI7 (9%) 33 (87%) 
I6 (1%) ? (5%) 
n = I55 n = 319 
I06 (68%) 236 (7%) 0.23 
X2 (53%) I67 (51%) 
144 (93V) 306 (93V) 
4 (3%) I7 (5’:;) 
IX (l2V) 3x (1%) 0.62 
n = 137 n = 791 
106 (77%) 246 185%) 0.007 
33 (Ilrlr) 51 (15%) 0.01 
‘.Chi-square test to compare LAD versus LCx and RCA patency. CABG 
= coronary bypass gaft surgery: PTCA = percutaneous, transluminal coro- 
nary angioplasty; other abbreviations as in Table I. 
repeat catheterization and revascularization before the 7 day 
follow-up study was required in 12% of patients and was 
independent of arterial distribution. Patency rates were well 
maintained at 7 days in the left anterior descending and left 
circumflex arteries. but the right coronary artery had a 21% 
I week reocclusion rate (p = 0.01). 
Reperfirsion rrrtes after H-PA inji~sion were lower, al- 
though the difference was not statistically significant, when 
lesion location in the artery was proximal compared with 
distal (69 versus 76%. p = 0.14). Final catheterization 
laboratory patency rates immediately after angioplasty were 
not influenced by lesion location (95 versus 93%). One week 
patency rates were higher, but not significantly, when lesion 
location was proximal (87 versus 81%, p = 0.12). The 
reocclusion rate of distal and proximal lesions did not differ 
statistically. 
Left ventricular function (Table 5). Regional wall motion 
in the infarct zone improved significantly during the 1st week 
of hospitalization regardless of arterial distribution. A small 
but significant improvement in ejection fraction occurred 
only when the left anterior descending artery was the infarct- 
related artery. However. regression analysis revealed that 
after adjustments were made for acute ejection fraction and 
acute regional wall motion, neither the infarct-related artery 
nor the lesion location predicted improvement in regional or 
global left ventricular function. 
Mortality (Table 6). The in-hospital mortality rate was 
6.4% in patients with a documented infarct-related artery 
and was not influenced by arterial distribution. However, 
mortality was twice as likely with a proximal lesion location 
(p = 0.15). Importantly, the lesion was proximal to the first 
septal perforator branch in 10 of the 11 patients who died in 
the group whose infarct area was supplied by the left anterior 
descending artery. All nine patients who died with the right 
coronary artery as the infarct-related artery had a lesion 
Discussion 
Coronary artery patency. Data on the influence of infarct 
location on arterial patency rates after thrombolytic therapy 
have been conflicting. Whereas some investigators (14) have 
reported a higher reperfusion rate after streptokinase infu- 
sion in the left anterior descending than in other arteries, 
other investigators (15.16) have reported similar reperfusion 
rates in the left anterior descending and the right coronary 
artery with decreased success in the left circumflex artery, 
and one registry reported (17) equivalent patency rates in all 
three arteries. Using 80 mg of double chain rt-PA. the TIMI-I 
trial (18) found superior reperfusion in the left anterior 
descending artery. The present study used IS0 mg of single 
chain rt-PA and found equivalent left anterior descending 
artery reperfusion compared with the TIMl-1 trial, but 
improved left circumflex and right coronary artery reperfu- 
sion. Whereas Tendera et al. (14) found proximal lesions 
were more easily reperfused. the TIMI-I trial (18) showed no 
difference in reperfusion rates by lesion location, and our 
study demonstrated a trend favoring reperfusion of more 
distal lesions. It is probable that reperfusion rates are 
influenced by a number of factors including thrombolytic 
agent (9. IO), route of administration (l9), time to adminis- 
tration (20). dose (21). thrombus volume (18). arterial 
branching (14,18), collateral flow (14) and lesion geometry. 
Although preservation of left ventricular function has 
been considered the necessary prerequisite for reducing 
mortality due to myocardial infarction, two multicenter 
studies have proved survival benefit when early arterial 
Table 4. Arterial Patency by Lesion Location in 329 Patients 
LAD LCx Kc‘.4 Total 
(n = 133) (n = 41) (n =: 1551 In =: 329) p Value” 
90 min patency 
Proximal 
Distal 
Day 7 patency 
Proximal 
Distal 
Keocclusion 
Proximal 
Distal 
71 (74%) 7 (54%) Sl (65%) 179 (69%t 
p = 0.14 
31 (X6%) ?I (7X%) 5.5 (71%1 1117 (76%) 
77 (94%) IO (77Vl 51 (Xl%1 I39 (X7’lr) 
p = 0.12 
27 (X7%) 71 (91%) S? (74%) 100 (81%) 
IO (10%) I (XV) IS (IY%) I6 (14%) 
p = 0.33 
6 (17%) I (4%) IX (23%) 15 c 18%) 
“Chi-square telt to compare LAD versus LCx and RCA patency. Ahhre- 
vtations as tn Table I. 
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Table 5. Left Ventricular Function After Thrombolytic Therapy in 264 Patients 
LAD LCX RCA 
(n = 105) (n = 31) (n = 128) 
Total 
(n = 264) 
Regional wall motion (SD/chord) 
Acute 
Follow-up 
Delta 
p Value* 
Ejection fraction (%) 
Acute 
Follow-up 
Delta 
p Value* 
-2.8 ? 0.9 -2.1 2 1.3 
-2.3 2 1.1 1.6 ? 1.2 
0.5 + 0.9 0.5 2 0.9 
0.0001 0.008 
47 + II 
502 12 
2.5 t 10 
0.018 
54 ? 9 
54 ? 9 
Ot8 
0.78 
-2.5 f 1.1 
-2.2 i 1.2 
0.3 + 1.0 
0.028 
56 t 9 
56 % 9 
-0.5 + 8 
0.62 
-2.6 2 I.1 
-2.2 t 1.2 
0.4 + 1.0 
0.0001 
52 2 II 
53 2 11 
I?9 
0.27 
Wilcoxon signed rank test to compare acute and follow-up studies. Delta = difference between acute and 
follow-up values; other abbreviations as in Table 1. 
patency is achieved in the absence of myocardial salvage 
(22-24). One year mortality in the Western Washington 
Intracoronary Streptokinase trial (22) was 2.5% in patients 
with successful reperfusion whereas it was 14.5% when 
reperfusion did not occur. Likewise, 6 month mortality in 
the TIMI-I trial (23) was 5.6% with successful reperfusion, 
but 12.5% in patients with unsuccessful reperfusion. Limi- 
tation of infarct expansion (25) and increased ventricular 
fibrillation threshold (26) have been postulated as two pos- 
sible mechanisms of reduced mortality. Thus, restoring 
arterial patency alone may be a sufficient goal in acute 
interventional strategies. If so, the sequential approach of 
thrombolytic therapy followed by selective coronary angio- 
plasty employed in this study could be the optimal treatment 
strategy because a 93% early patency rate was achieved. 
Arterial reocclusion occurred in only 15% of the patients 
in this study, compared with 24% in the TIMI-I study (18). 
This discrepancy is best explained by the maintenance 
infusion of rt-PA employed in this study (27), but could 
partly be due to the use of single chain rt-PA. A dispropor- 
tionate reocclusion rate of 21% existed when the right 
coronary artery was the infarct-related artery. A similar 
experience was reported with streptokinase; a 20% 4 week 
reocclusion rate of this artery was reported in the (ISAM) 
trial (8) compared with 9% for the left anterior descending 
coronary artery, and a 21% 1 year reinfarction rate was 
reported in the Netherlands trial (4) after inferior infarction 
versus 8% after anterior infarction. Thus, new strategies to 
Table 6. In-Hospital Mortality in 376 Patients After 
Thrombolytic Therapy 
LAD LCX RCA 
Proximal lesion IO/l IO (9%) 2115 (13%) 5190 (6%) 
Distal lesion 1143 (2%) 2133 (6%) 4185 (5%) 
Total 111153 (7%) 4148 (8%) 91175 (5%) 
Abbreviations as in Table I. 
Total 
171215 (8%) 
71161 (4%) 
241376 (6%) 
decrease reocclusion rates would particularly improve the 
results of acute intervention in inferior infarction. 
Left ventricular function. Even though a small but signif- 
icant increase in regional wall motion was observed for each 
arterial distribution in this study, serial improvement in 
global left ventricular ejection fraction did not occur. The 
same results were reported after intracoronary streptokinase 
therapy in the Netherlands trial (2), where patency and time 
to treatment were equivalent to those in this trial. The early 
follow-up study we employed (7 days) may not have mea- 
sured maximal improvement in ventricular function because 
of persistence of stunned myocardium (28). Alternatively, 
the high early reperfusion rate may have preserved initial left 
ventricular function such that further recovery of global 
function was not demonstrable. Future trials involving 
thrombolytic therapy will be unlikely to have placebo con- 
trol groups because the randomized streptokinase trials have 
conclusively demonstrated improvement in ventricular func- 
tion and reduction in mortality in treatment groups. The 
inability of the Netherlands trial (2), the TIMI-I trial (24) and 
this trial to demonstrate serial improvement in ejection 
fraction suggests that variables other than global ejection 
fraction may be needed to judge therapeutic efficacy in 
future trials. 
It is noteworthy that this trial and the other three multi- 
center trials (2,5,24) of intravenous therapy that measured 
left ventricular function found improvement in infarct zone 
regional wall motion independent of infarct location; this is 
despite the fact that the left ventricular ejection fraction in 
inferior infarction is often >50% and that reocclusion rates 
for the right coronary artery after either streptokinase or 
rt-PA are twice those for the left anterior descending artery. 
Significant improvements in global left ventricular ejection 
fraction have been shown in inferior infarction after throm- 
bolytic therapy (2,5), particularly when time to treatment is 
short (29), initial left ventricular ejection fraction is de- 
pressed (30), high ST segment elevation (3) or marked 
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reciprocal anterior lead changes are present (3.31) or when 
patency is sustained (29,3 1). 
Mortality. Although this trial was not designed to evalu- 
ate the effect of thrombolytic therapy on mortality, the 
in-hospital mortality rate of 6.4% is equivalent to that 
reported in the treatment groups of the randomized strepto- 
kinase trials (1,5,7,32) and lower than that reported in their 
placebo groups or in the recent natural history studies (33- 
35). The major survival benefit in this study and others 
appears to be in patients with anterior infarction who have a 
12 to 18% hospital mortality rate when treated by noninter- 
ventional methods (1,7,32-35) compared with 6 to 14% when 
treated with thrombolytic agents and sometimes angioplasty 
(1,5,7,32). Because this study and others (2.524) have 
shown that improvement in regional and global left ventric- 
ular function occurs independent of infarct location after 
thrombolytic therapy. other factors such as limitation of 
infarct expansion (25) or increased ventricular fibrillation 
threshold (26) must be imparting a preferential survival 
benefit after thrombolytic therapy in patients with anterior 
infarction. 
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